Improving anti-drug antibody assay performance in Gyrolab for therapeutic recombinant antibody Infliximab
Monoclonal antibodies can be used as targeting therapies for several diseases. One major concern when using these therapies is anti-drug antibodies which may hamper the drugs efficiency. Gyrolab is an automated platform which can be used to develop bridging immunoassays where the anti-drug antibodie...
| Main Author: | |
|---|---|
| Format: | Others |
| Language: | English |
| Published: |
Linköpings universitet, Institutionen för klinisk och experimentell medicin
2014
|
| Online Access: | http://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-111527 |